Document is current
Any future updates will be listed below
-
Authors
Asla, Queralt
Garrido, Maite
Urgell, Eulàlia
Terzan, Sílvia
Santos, Alicia
Fernández, Mercè
Varghese, Nimmy
Atila, Cihan
Calabrese, Anna
Biagetti, Betina
Plessow, Franziska
Gich, Ignasi
Christ-Crain, Mirjam
Eckert, Anne
Webb, Susan M.
Lawson, Elizabeth A.
Aulinas, Anna https://orcid.org/0000-0002-1205-7114
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (FIS PI20/01165)
Instituto de Salud Carlos III (JR19/00013)
- License Information
-
More Information
Article History
Received: 5 October 2024
Accepted: 13 January 2025
First Online: 18 January 2025
Declaration
:
: EAL receives grant support and research study drug from Tonix Pharmaceuticals and receives royalties from UpToDate. EAL and/or immediate family member holds stock in Thermo Fisher Scientific, Zoetis, Danaher Corporation, Intuitive Surgical. EAL is an inventor on US provisional patent application no. 63/467,980 (Oxytocin-based therapeutics to improve cognitive control in individuals with attention deficit hyperactivity disorder). No other conflicts of interest, financial or otherwise, are declared by the authors.
